Protocol Specific Reserach Support

西蒙斯癌症中心的最高优先事项之一是有效地将科学发现转化为 以降低癌症的发病率和死亡率。德州大学西南分校有着悠久的传统 在基础科学方面的卓越表现，以及最近明确定义的癌症中心项目的组织， 不适当的科学家是可转化癌症一些最重要的最新进展的原因 生物学。Invesfigator激活的早期跨区域研究试验需要重要的监管数据 管理和研究护理资源，这些资源并非总是通过传统机制获得 以一种时髦的方式。特定于协议的研究支持提供了快速翻译的机制 将不适合的癌症科学带到临床。 这些资金旨在支持西蒙斯癌症中心的方案优先事项。标准 用于评估特定于协议的研究支持的适宜性包括： 1.由Invesfigator发起的具有特殊科学价值的可行性/第一阶段或试点试验 2.试验必须符合以下一项或多项标准： A.被测试的试剂或概念是德州大学西南临床前科学的产品。 B.试验将产生外部同行审查资金或发展为 规模更大、多机构参与的第二阶段或第三阶段试验。 C.这项试验促进了基础和临床科学家之间的重大互动，以实现重要的 相关客体。 这笔资金的优先事项通过双月刊传达给以疾病为导向的团队(DOTS) DOT领导人会议和计划领导人每两个月举行一次的会议。信息流既有 指导这些会议，因为能源部领导人可以审查发起人指定的协议想法和计划 领导者可以推广准备好进行临床评估的试剂或分子。鼓励个别网点 根据癌症中心的优先事项开发和完善方案概念，并寻求反馈 临床研究副主任在开发过程的早期。

One of the highest priorities of the Simmons Cancer Center is to efficiently translate scientific discoveries to the clinic in order to reduce cancer morbidity and mortality. U.T. Southwestem has a long tradifion of excellence in the basic sciences and with the recent organizafion of well-defined Cancer Center programs, insfitufional scienfists are responsible for some of the most important recent advances in translatable cancer biology. Early phase Invesfigator-inifiated translafional research trials require significant regulatory, data management and research nursing resources that are not always available through traditional mechanisms in a fimely fashion. Protocol-specific research support provides a mechanism for rapidly translating insfitutional cancer science to the clinic. These funds are intended to support the programmatic priorifies of the Simmons Cancer Center. Criteria used to assess suitability for Protocol-Specific Research support include: 1. Invesfigator-initiated feasibility/Phase I or pilot trial with exceptional scientific merit 2. The trial must meet one or more of the following criteria: a. The agent or concept to be tested is a product of U.T. Southwestern preclinical science. b. The trial will generate data required for external peer-reviewed funding or for development into a larger, multi-institutional phase II or III trial. c. The trial promotes significant interacfion between basic and clinical scienfists to achieve important correlative objecfives. Priorities for this funding are communicated to the Disease Oriented Teams (DOTs) through the bi-monthly DOT leaders meetings and to the Program Leaders at their bi-monthly meefings. Information flows both direcfions at these meefings as DOT leaders can vet invesfigator inifiated protocol ideas and Program leaders can promote agents or molecules ready for clinical evaluafion. Individual DOTs are encouraged to develop and refine protocol concepts responsive to the Cancer Center priorifies and to seek feedback from the Associate Director for Clinical Research early in the development process.